This is a working overview of GLP-1 analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
== Etymology == The word muscle comes from Latin musculus, diminutive of mus meaning mouse, because the appearance of the flexed biceps resembles the back of a mouse. The same etymology is found in Greek, in which μῦς, mȳs, means both "mouse" and "muscle".
EAS Sports Nutrition (formerly Experimental & Applied Sciences) was a distributor of creatine nutritional supplements with approximately 300 staff, annual sales exceeding $300 million, and offices/distributors in 54 countries.
The second safeguard clause was a commitment that nothing should be done which might prejudice the rights of the Jewish communities in other countries outside of Palestine. The original drafts of Rothschild, Balfour, and Milner did not include this safeguard, which was drafted together with the preceding safeguard in early October, in order to reflect opposition from influential members of the Anglo-Jewish community. Lord Rothschild took exception to the proviso on the basis that it presupposed the possibility of a danger to non-Zionists, which he denied. The Conjoint Foreign Committee of the Board of Deputies of British Jews and the Anglo-Jewish Association had published a letter in The Times on 24 May 1917 entitled Views of Anglo-Jewry, signed by the two organisations' presidents, David Lindo Alexander and Claude Montefiore, stating their view that: "the establishment of a Jewish nationality in Palestine, founded on this theory of homelessness, must have the effect throughout the world of stamping the Jews as strangers in their native lands, and of undermining their hard-won position as citizens and nationals of these lands." This was followed in late August by Edwin Montagu, an influential anti-Zionist Jew and Secretary of State for India, and the only Jewish member of the British Cabinet, who wrote in a Cabinet memorandum that: "The policy of His Majesty's Government is anti-Semitic in result and will prove a rallying ground for anti-Semites in every country of the world."
Tui na (推拿) is a form of massage, based on the assumptions of TCM, from which shiatsu is thought to have evolved. Techniques employed may include thumb presses, rubbing, percussion, and assisted stretching.
== Therapies == A decade after the discovery of the RNAi mechanism in 1998, the pharmaceutical sector heavily invested in the research and development of siRNA therapy. There are several advantages that this therapy has over small molecules and antibodies. It can be administered quarterly or every six months. Another advantage is that, unlike small molecules and monoclonal antibodies that need to recognize a specific protein conformation, siRNA functions by Watson-Crick basepairing with mRNA. Therefore, any target molecule that needs to be treated with high affinity and specificity can be selected if the right nucleotide sequence is available. One of the biggest challenges researchers needed to overcome was the identification and establishment of a delivery system through which the therapies would enter the body. Another was that the immune system often mistakes RNAi therapies for remnants of infectious agents, which can trigger an immune response. Animal models did not accurately represent the degree of immune response seen in humans, and despite the promise of the treatment, investors divested from RNAi. However, there were a few companies that continued with the development of RNAi therapy for humans. Alnylam Pharmaceuticals, Sirna Therapeutics and Dicerna Pharmaceuticals are few of the companies still working on bringing RNAi therapies to market. It was learned that almost all siRNA therapies administered in the bloodstream accumulated in the liver. That is why most of the early drug targets were diseases that affected the liver.
Sources: en.wikipedia.org
=== Simple epithelium === Simple epithelium is a single layer of cells with every cell in direct contact with the basement membrane that separates it from the underlying connective tissue. In general, it is found where absorption and filtration occur. The thinness of the epithelial barrier facilitates these processes. In general, epithelial tissues are classified by the number of their layers and by the shape and function of the cells. The basic cell types are squamous, cuboidal, and columnar, classed by their shape.
== Measurement == The glycemic index of a food is defined as the incremental area under the two-hour blood glucose response curve (AUC) following a 12-hour fast and ingestion of a food with a certain quantity of available carbohydrate (usually 50 g). The AUC of the test food is divided by the AUC of the standard (either glucose or white bread, giving two different definitions) and multiplied by 100. The average GI value is calculated from data collected in 10 human subjects. Both the standard and test food must contain an equal amount of available carbohydrate. The result gives a relative ranking for each tested food. Foods with carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream tend to have a high GI; foods with carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, tend to have a low GI. A lower glycemic index suggests slower rates of digestion and absorption of the foods' carbohydrates and can also indicate greater extraction from the liver and periphery of the products of carbohydrate digestion. The current validated methods use glucose as the reference food, giving it a glycemic index value of 100 by definition. This has the advantages of being universal and producing maximum GI values of approximately 100. White bread can also be used as a reference food, giving a different set of GI values (if white bread = 100, then glucose ≈ 140).
Blood tests can be done to determine if a patient has high levels of antibodies that are indicative of the disease, such as antinuclear antibody (ANA) and rheumatoid factor (because Sjögren's is considered to occur frequently “secondary” to rheumatoid arthritis), which are associated with autoimmune diseases. Typical Sjögren’s disease ANA patterns are SSA/Ro and SSB/La, of which anti-SSB/La is far more specific; anti-SSA/Ro is associated with numerous other autoimmune conditions, but is often present in Sjögren’s disease. However, anti-SSA and anti-SSB tests are frequently not positive in Sjögren’s.
== Principle == Delayed neutrons are associated with the beta decay of the fission products. After prompt fission neutron emission the residual fragments are still neutron rich and undergo a beta decay chain. The more neutron rich the fragment, the more energetic and faster the beta decay. In some cases the available energy in the beta decay is high enough to leave the residual nucleus in such a highly excited state that neutron emission instead of gamma emission occurs. Using U-235 as an example, this nucleus absorbs thermal neutrons, and the immediate mass products of a fission event are two large fission fragments, which are remnants of the formed U-236 nucleus. These fragments emit two to three free neutrons (2.43 on average), called "prompt" neutrons. A subsequent fission fragment occasionally undergoes a stage of radioactive decay (which is a beta minus decay) that yields a new nucleus (the emitter nucleus) in an excited state that emits an additional neutron, called a "delayed" neutron, to get to ground state. These neutron-emitting fission fragments are called delayed neutron precursor atoms. The longest-lived groups can be traced to specific decay chains. In about 70% of 87Br beta decays (half-life 55 s), the 87Kr daughter is left in a nuclear state above the 5.4 MeV needed to eject its last neutron; it promptly releases a neutron, ending as stable 86Kr. The neutron emission rate is set by the rate of formation of 87Kr, so the group carries the 55 s half-life of the precursor.
Sources: en.wikipedia.org
The character controlled throughout the game was a concocted version of Simon, and all the monsters represented the trauma in his mind. Cry of Fear has five different endings depending on the player's choices.
Widespread travel by naturalists in the early-to-mid-19th century resulted in a wealth of new information about the diversity and distribution of living organisms. Of particular importance was the work of Alexander von Humboldt, which analyzed the relationship between organisms and their environment (i.e., the domain of natural history) using the quantitative approaches of natural philosophy (i.e., physics and chemistry). Humboldt's work laid the foundations of biogeography and inspired several generations of scientists.
It was the country's only NGO specializing in media issues, Internet access, and media monitoring during election campaigns. It had operated without government approval, and had monitored violations of journalists' rights and had taken up the cause of the ban on the dissemination of many newspapers and magazines. Ba'athist Syrian security forces arrested and beat up protestors on 15 June 2020. The protest started on 7 June 2020, in front of the governorate center against government's failure of handling economic downfall, deteriorating living conditions and corruption. HRW appealed the Syrian authority to release the peacefully protesting detainees. Pro-regime journalists who were allowed to report within the country were arrested by security forces over social media posts or ambiguous charges like being "out of line".
== History == In 1938, the Clinical Maternity Hospital No.3 of Yerevan was established. The current building has been operational since 1964. In 2001, the maternity hospital was transformed into the Shengavit Medical Center with a share belonging to the Yerevan municipality. In 2002, the ownership of the hospital became the property of the staff and it was reorganized into a multi-disciplinary clinical-diagnostic institution.
Esketamine has faster clearance and stronger dopamine inhibition than arketamine, contributing to its dissociative and psychotomimetic effects. In the form of racemic ketamine, esketamine was first synthesized in 1962 and introduced for medical use as an anesthetic in 1970. Enantiopure esketamine was introduced for medical use as an anesthetic in 1997 and as an antidepressant in 2019. It is used as an anesthetic in the European Union and as an antidepressant in the United States and Canada. Due to misuse liability as a dissociative, esketamine is a controlled substance.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.